ABL Texcell Diagnostics SA Stock Price

ABL Texcell Diagnostics SA provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA, hepatitis-B Virus (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV), BK virus (BKV), human papillomavirus (HPV), respiratory syncytial virus (RSV), and salmonella; real time PCR assays; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, next generation sequencing (NGS) library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as ABL Diagnostics Société anonyme and changed its name to ABL Texcell Diagnostics SA in April 2022. The company is headquartered in Woippy, France. ABL Texcell Diagnostics SA operates as a subsidiary of Advanced Biological Laboratories (ABL) S.A.